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Abstract: Background: The translation of genomic discoveries to the clinic is the cornerstone of
precision medicine. However, incorporating next generation sequencing (NGS) of hematologic
malignancies into clinical management remains limited. Methods: We describe 235 patients who
underwent integrated NGS profiling (406 genes) and analyze the alterations and their potential
actionability. Results: Overall, 227 patients (96.5%) had adequate tissue. Most common diagnoses
included myelodysplastic syndrome (22.9%), chronic lymphocytic leukemia (17.2%), non-Hodgkin
lymphoma (13.2%), acute myeloid leukemia (11%), myeloproliferative neoplasm (9.2%), acute
lymphoblastic leukemia (8.8%), and multiple myeloma (7.5%). Most patients (N = 197/227
(87%)) harbored ≥1 genomic alteration(s); 170/227 (75%), ≥1 potentially actionable alteration(s)
targetable by an FDA-approved (mostly off-label) or an investigational agent. Altogether, 546
distinct alterations were seen, most commonly involving TP53 (10.8%), TET2 (4.6%), and DNMT3A
(4.2%). The median tumor mutational burden (TMB) was low (1.7 alterations/megabase); 12%
of patients had intermediate or high TMB (higher TMB correlates with favorable response to
anti-PD1/PDL1 inhibition in solid tumors). In conclusion, 96.5% of patients with hematologic
malignancies have adequate tissue for comprehensive genomic profiling. Most patients had unique
molecular signatures, and 75% had alterations that may be pharmacologically tractable with gene- or
immune-targeted agents.
Keywords: next generation sequencing; lymphoid malignancies; myeloid malignancies; precision
medicine
Cancers 2019, 11, 11; doi:10.3390/cancers11010011 www.mdpi.com/journal/cancers
Cancers 2019, 11, 11 2 of 17
1. Introduction
Recent advances in next generation sequencing (NGS) have allowed for unprecedented insights
into the genomic alterations that underlie oncogenesis, tumor biology, and survival. NGS permits
identification of genomic alterations that not only inform a more granular subclassification of disease
with various prognostic and predictive features but may also guide therapy selection [1]. Cumulative
gains in understanding of cancer genomics and immuno-oncology are being rapidly translated into
clinical practice, particularly for metastatic solid tumors, shifting the treatment paradigm from cytotoxic
chemotherapy to a biologically informed approach where oncogenic alterations are matched with
targeted agents [2,3]. The drug-target pairing that aligns a deranged molecular pathway with a cognate
therapeutic agent constitutes the hallmark of precision medicine, and has demonstrated superior
response rates as compared to nonselective chemotherapy in tumors such as melanoma, lung cancer,
and chronic myelogenous leukemia [4,5]. There is now a plethora of genotype-matched therapeutics
that have been Food and Drug Administration (FDA)-approved for the treatment of advanced solid
tumors across a wide array of histologies.
Matched targeted therapy has also proven effective in several hematologic malignancies.
For instance, chronic myelogenous leukemia (CML) is the poster child for a disease transformed
by matched targeted therapy. Indeed, imatinib mesylate, which inhibits the enzymatic activity of the
aberrant BCR-ABL1 kinase, the hallmark of CML, has extended overall survival to near-normal life
expectancy. Despite the unequivocal success of tyrosine kinase inhibitors (TKI) in CML, these types of
practice-changing, rationally developed, targeted agents have not been broadly implemented in the
treatment of many lymphoid and myeloid malignancies. As a result, despite the vast heterogeneity
of hematopoietic tumors, most of the patients suffering from these disorders are still treated with
non-specific cytotoxic chemotherapy. While this “one size fits all” approach is effective for many
patients, it is clear that a significant proportion of patients, particularly those with adverse prognostic
features, often relapse. The poorer outcomes are arguably because, despite cytotoxic chemotherapy,
the driver oncogenic alterations persist, uninhibited, in the residual post-chemotherapy clones. In the
relapsed setting, the standard salvage regimens rely on more intensive chemotherapy, followed by
hematopoietic stem cell transplantation (HSCT), often associated with poor tolerability and significant
morbidity, particularly in older patients [6]. Thus, understanding the molecular crosstalk that leads to
disease progression and selectively targeting alterations within these signaling pathways remains a
critical and unmet medical need.
To date, intense investigation into molecular underpinnings of hematologic disease has led to
the identification of key recurrent mutations such as MYD88L265P in lymphoplasmacytic lymphoma
(LPL), BRAFV600E in hairy cell leukemia (HCL), and FLT3 in acute myelogenous leukemia (AML)
that can be successfully targeted with cognate agents—ibrutinib, vemurafenib, and midostaurin
respectively; producing encouraging results [7–9]. Undoubtedly, further insight into the genomic
landscape of hematologic malignancies may help elucidate key molecular alterations and potentially
inform treatment selection.
Herein, we analyze the genomic profiles of 235 patients with various hematologic malignancies
for whom comprehensive genomic profiling (CGP) had been performed. We examined the mutational
burden as well as the type and frequency of potentially actionable alterations across a wide variety of
hematologic diagnoses to better delineate the mutational landscape of these disorders, providing a
foundation for precision medicine trials in the hematologic malignancy clinical setting.
2. Results
2.1. Patient Characteristics
Tumor samples from 235 patients (133 men (59%) and 94 women (41%)) were collected. Of these,
227 subjects (96.5%) had adequate tissue quantity and purity for genomic analysis. Thirty patients had
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no genomic alterations, while 87% of patients (197/227) demonstrated at least one molecular alteration
(variants of unknown significance (VUSs) were excluded) (Figure 1).
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.
The most common malignancy in this cohort was myelodysplastic syndrome (22.9%), chronic
lymphocytic leukemia (17.2%), non-Hodgkin lymphoma (13.2%), acute myeloid leukemia (11%),
myeloproliferative neoplasm (9.2%), acute lymphoblastic leukemia (8.8%), and multiple myeloma
(7.5%) (Table 1). The most common tissue source for NGS analysis was peripheral blood (N = 99
patients (44%)) or bone marrow (N = 86 (38%)), followed by lymph node (N = 17 (7%)) and other
(N = 25 (11%)).
Table 1. Patient characteristics (N = 227 patients with adequate tissue for comprehensive genomic
profiling (CGP)).
Patient Demographics and Baseline Characteristics
Gender:
Men (%); Women (%) 133 (59%); 94 (41%)
Age:
Median age (range) 59 years (17–88)
Ethnicity:
Caucasian (%) 163 (71.8%)
Asian (%) 18 (8%)
Hispanic (%) 18 (8%)
African American (%) 8 (3.5%)
Other (%) 20 (8.8%)
Histologies:
Myeloid Disorders N = 124 (54.6%)
Myelodysplastic syndrome (MDS) 52 (22.9%)
Acute myeloid leukemia (AML) 25 (11%)
Myeloproliferative neoplasia (MPN) 21 (9.2%)
Multiple Myeloma (MM) 17 (7.5%)
Chronic myeloid leukemia (CML) 4 (1.8%)
Other myeloid disorders 5 (2.2%)
Lymphoid disorders N = 103 (45.4%)
Chronic lymphocytic leukemia (CLL) 39 (17.2%)
Acute lymphocytic leukemia (ALL) 20 (8.8%)
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Table 1. Cont.
Patient Demographics and Baseline Characteristics
Diffuse large B-cell lymphoma (DLBCL) 18 (7.9%)
Follicular lymphoma (FL) 6 (2.6%)
Marginal zone lymphoma (MZL) 4 (1.8%)
Anaplastic large cell lymphoma (ALCL) 2 (0.9%)
Castleman disease 2 (0.9%)
Other lymphoid disorders 12 (5.3%)
Summary of alterations
Number of patients with alterations 197 (87%)
Number of patients with potentially actionable alterations 170 (75%)
Median number of alterations/patient (range) 3 (0–14)
Median number of potentially actionable alterations/patient (range) 1 (0–7)
Total alterations 698
Number of distinct alterations 546
Number of distinct potentially actionable alterations 256
2.2. CGP Results
The genomic landscape of distinct alterations identified across hematopoietic malignancies is
depicted in Figure 2.
Figure 2. The genomic landscape of distinct, clinically relevant gene alterations across hematologic
cancers. Molecular alterations are organized by gene sets derived from MSigDB Collection2
(Version 6.1) [10–12].
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The median number of alterations detected per patient was 3 (range, 0–14). The majority of
patients (N = 197/227 (87%)) harbored at least one alteration. Of the total distinct aberrations,
alterations in TP53 (N = 59), TET2 (N = 25) and DNMT3A (N = 23) were among the most frequent
aberrations. (Figures 3 and 4).
Figure 3. Frequency of most common alterations across various hematologic histologies.
A total of 546 distinct alterations were identified by NGS in the entire cohort of 227 patients
(Table 1). Types of alterations identified included substitutions, indels, copy number alterations
(CNAs), and gene fusions. The most frequent types of alterations were mutations (85% of all alterations
(594/698)), followed by fusion/rearrangement (7% (48/698)), copy loss (6% (42/698)), and copy
gain/duplication/amplifications (2% (14/698)) (Figure 5).
In at least one patient, one hundred and forty-eight distinct genes were altered. The vast majority
of patients (95.5%) had distinct molecular profiles, 4.5% of patients had identical molecular signatures
(solitary alterations that were identical in at least one other patient involving the following genes:
JAK2 V617F (.5%), TP53 R273H (1%), SF3B1 K700E (1%)). (An identical molecular portfolio/signature
implies that both the genes involved and the precise loci altered in those genes were identical).
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Figure 4. Overview of hematopoietic malignancies and most frequent alterations. The frequency of
most common alterations per histology type. Total number of distinct alterations N = 546. The graph
displays unique alterations that occur in ≥3% of patients with the specified histology.
Figure 5. Types of molecular alterations identified.
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2.3. TMB
In our cohort, 219 patients had data for TMB. TMB ranged from 0.4 to 140, with a median TMB
of 1.7 mutations per megabase. The majority of patients (84%) had low TMB (≤1–5 mutations/MB);
12%, intermediate TMB (>5 to ≤19 mutations/MB); and only 2%, high TMB (≥20 mutations/MB)
(Figure 6). TMB of myeloid neoplasms was lower than that for lymphoid malignancies (median = 0.9
mutations/MB (range, 0.8–12) versus 2.5 (range, 0.4–140) (p = 0.0012).
Figure 6. Tumor Mutation Burden (TMB) across hematologic malignancies. Note: N = 219 total number
of patients analyzed for TMB. The majority of patients (84%) had low TMB (≤1–5 alterations/MB),
12% were found to have intermediate TMB (>5 to ≤19 alterations/MB), and only 2% of the patients
harbored high TMB (≥20 alterations/MB).
2.4. Actionable Alterations
Potentially actionable mutations were identified in 75% of patients with adequate tissue (170/227).
Of these, 32 patients (14% of the 227) had ≥1 alteration theoretically actionable by an on-label FDA
approved drug; 112 patients (49% of 227), by an off-label FDA-approved drug; and, of the remainder,
26 patients had an alteration actionable by an experimental drug. Pharmacologically tractable aberrations
were found across all hematological malignancies (Table 2).
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Table 2. Genomic alterations and examples of potential targeted (either on- or off- label) therapeutic.
Gene Alteration Gene Function Examples of Potential on/off-Label Therapy
Examples of Potential
Experimental
Therapy/Clinical Trial *
Ref.
ABL1/2 ABL (Abelson tyrosine-protein) kinase regulates cell survival anddivision/differentiation Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib
APC APC (adenomatous polyposis coli) is a tumor suppressor, regulating celldivision/adhesion, controls Wnt signaling pathway Sulindac (Tankyrase inh) [13]
ARID1A ARID1A (AT-rich interactive domain-containing protein 1A) regulatestranscription Dasatinib, EZH2 inh.
Talazoparib Tosylate
NCT02286687 **
ASXL1 ASXL1 (additional sex combs-like1) regulates transcription andubiquitin-proteasome protein degradation via BAP pathway. Cabozantinib [14]
ATM ATM (ataxia telangiectasia mutated) regulates DNA damage responsevia the PI3K-like protein kinase pathway Olaparib [15]
BCL2 BCL2 (B-cell lymphoma 2) regulates apoptosis Venetoclax [16]
BRAF BRAF regulates cell growth via MAPK (RAF-MEK-ERK) signalingcascade
Dabrafenib, Regorafenib, Trametinib, Vemurafenib,
Cobimetinib [17]
BRCA2 BRCA2 (breast cancer 1/2) regulates DNA double-strand break repair Olaparib, Niraparib, Rucaparib
BRIP1 BRIP1 (BRCA1-interacting protein 1) functions in DNA repair Olaparib
BTK BTK (Bruton’s tyrosine kinase) regulates B-cell receptor signaling andB-cell development Ibrutinib, Acalabrutinib [18]
CCND2 CCND1/3 (cyclin D1/3) regulates cell cycle via CDK4/6 Palbociclib [19]
CD274 CD274 (cluster of differentiation 274) encodes immune inhibitoryreceptor B7-H1, also known as programmed cell death ligand-1 (PD-L1)
Atezolizumab, Avelumab, Durvalumab,
Nivolumab, Pembrolizumab
CD79B
CD79A/B (cluster of differentiation 79) complexes with B-cell receptor,
mediates downstream signaling to the NF-kB, PI3K, MAPK and NF-AT
pathways
Ibrutinib Polatuzumab vedotin [20]
CDK4 CDK4 (cyclin-dependent kinase 4) regulates cell cycle Palbociclib, Ribociclib [19]
CDKN2A/B CDKN2A (cyclin dependent kinase inhibitor encodes tumor suppressorsand regulates cell cycle; loss results in increased CDK4/6 Palbociclib, Ribociclib [19]
CSF1R CSF1 (colony stimulating factor 1) regulates differentiation and survival Chiauranib NCT03074825 **
CXCR4 CXCR4 (C-X-C chemokine receptor type 4) regulates hematopoiesis andCD20 expression Plerixafor BMS-936564 NCT01120457 ** [21]
DNMT3A DNMT3A (DNA methyltransferase 3A) regulates gene expression Azacitidine, Decitabine [22]
EP300 Histone acetyltransferase p300 regulates transcription via chromatinremodeling Mocetinostat NCT02282358 **
ERBB4 Member of the EGFR (epidermal growth factor receptor) regulatesproliferation
Trastuzumab, Pertuzumab Afatinib, Erlotinib,
Lapatinib
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Table 2. Cont.
Gene Alteration Gene Function Examples of Potential on/off-Label Therapy
Examples of Potential
Experimental
Therapy/Clinical Trial *
Ref.
EZH2 EZH2 (enhancer of zeste-homolog 2) regulates DNA methylation andtranscription repression Tazemetostat (NCT02601950) ** [23]
FGFR3 FGFR3 (fibroblast growth factor receptor 3) promotes cell cycle viaactivation of RAS/MAPK/AKT pathway Lenvatinib, Pazopanib, Ponatinib, Regorafenib
FLT3 FLT3 (FMS-like tyrosine kinase 3) activates signaling of Akt1, RAS, ERK,and mTOR. Midostaurin, Gilteritinib Quizartinib [9,24]
FLT4 FLT4 (FMS like tyrosine kinase 4), also known as VEGFR-3 (vascularendothelial growth factor receptor 3)
Sorafenib, Sunitinib, Pazopanib, Axitinib,
Vandetanib, [25]
GNAS GNAS (Guanine nucleotide binding protein, α stimulating) regulatesadenylate cyclase via MAPK Trametinib
IDH1 IDH1 (isocitrate dehydrogenases 1) Azacitidine, Decitabine [26]
IDH/2 IDH2 (isocitrate dehydrogenases 2) regulates citric acid (Krebs) cycle andcell metabolism Enasidenib [27]
IGF1R IGF1R (insulin-like growth factor-1 receptor) mediates anti-apoptoticsignals Ganitumab NCT00562380 **
JAK1 JAK1 (Janus kinase 1) in involved in signal regulation Tofacitinib Fedratinib [28]
JAK2 JAK2 (Janus kinase 2) is involved in signal regulation Ruxolitinib [29]
KIT KIT (also known as c-Kit or CD117), activates PI3K/Akt andRAS/MAPK signaling pathway Imatinib, Midastaurin
KRAS KRAS (Kirsten rat sarcoma) regulates signal transduction via MAPKpathway
Cetuximab, Trametinib, Panitumumab,
Regorafenib [30]
MAP2K1 MAP2K1 (mitogen-activated protein kinase 1 (MKK1 or MEK1) mediatesRAS/RAF/MAPK pathway Cobimetinib, Selumetinib, Trametinib
MAP3K14 MAP3K14 (mitogen-activated protein kinase 14) also known asNF-kappa-B-inducing kinase Trametinib
MLL MLL (mixed lineage leukemia) encodes a histone methyltransferase EPZ-5676 NCT02141828 **
MSH2 MSH2 (MutS homolog2) is a tumor suppressor encodes DNA mismatchrepair (MMR) protein 2 Atezolizumab, Nivolumab Pembrolizumab
MSH6 MSH6 (MutS homolog 6) encodes DNA mismatch repair (MMR) protein6 involved in DNA repair Atezolizumab, Nivolumab Pembrolizumab
MYC MYC regulates cell cycle progression, apoptosis, proliferation BET inhibitors NCT02431260 **
MYD88 MYD88 (myeloid differentiation primary response gene 88) activatestranscription factor NFkB Ibrutinib, acalabrutinib (IRAK1 inh) zanubrutinib [7]
NF1/2 NF1 (neurofibromin 1/2) a GTPase-activating negative regulator of theRAS signaling pathway Everolimus, Temsirolimus, Trametinib
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Table 2. Cont.
Gene Alteration Gene Function Examples of Potential on/off-Label Therapy
Examples of Potential
Experimental
Therapy/Clinical Trial *
Ref.
NRAS NRAS (neuroblastoma RAS) mediates signal transduction viaRAF/MEK/ERK and PI3K Trametinib, Panitumumab [31]
PALB2 PALB2 (partner and localizer of BRCA2) Olaparib [32]
PDCD1LG2 Programmed cell death 1 ligand 2 (also known as CD273) essential forT-cell proliferation
Atezolizumab, Avelumab, Durvalumab,
Nivolumab, Pembrolizumab
PIK3CA PIK3CA (phosphatidylinositol 3-kinase (PI3K), which regulates thePI3K/AKT/MTOR axis
Everolimus, Temsirolimus, Copanlisib, Duvalisib,
Idelalisib Taselisib NCT02465060 **
PIK3R1 PIK3R1 (PI3K regulatory subunit alpha) Copanlisib NCT02369016 **
PTCH1 PTCH1 (Protein patched homolog 1) is a receptor for Sonic hedgehog(Shh) for gene transcription Vismodegib, Sonidegib [33]
PTEN PTEN (phosphatase and tensin homolog) is a tumor suppressor,functions via PI3K/AKT/mTOR pathway Everolimus, Temsirolimus [34]
PTPN11 PTPN11 (Tyrosine-protein phosphatase non-receptor type 11) activatesPI3K, MEK axis Trametinib, [35]
RET RET (rearranged during transfection) is a proto-oncogene Cabozantinib, Sorafenib, Vandetanib, Lenvatinib [36]
RUNX1
RUNX1 (Runt-related transcription factor, also known as acute myeloid
leukemia 1 protein (AML1), core-binding factor subunit alpha 2 (CBFA2)
is a tumor suppressor
Mocetinostat (MGCD0103) or
Sorafenib NCT00217646 **
STAT3 STAT3 (signal transducer and activator of transcription 3) encodes atranscription factor AZD9150 (NCT01839604) **
STK11 STK11 (serine/threonine kinase 11) functions as a tumor suppressor gene Dasatinib, Bosutinib, Everolimus, Temsirolimus
TET2 TET2 (Tet methylcytosine dioxygenase 2) regulates DNA demethylation Azacitidine, Decitabine [37]
TP53 TP53 (Tumor protein p53) is a tumor suppressor; loss leads tooverexpression of VEGF levels Bevacizumab, Pazopanib
Wee-1 inh, MDM inh,
PRIMA-1MET inhibitors. [38]
VHL VHL (von Hippel-Lindau) is a tumor suppressor activates theHIF/VEGF pathway
Axitinib, Bevacizumab, Everolimus, Pazopanib,
Sorafenib, Sunitinib, Temsirolimus, Vandetanib,
XPO1 XPO1 (exportin-1) regulates nuclear export of tumor suppressor genes Selinexor NCT02227251
* Experimental drugs in clinical trials are generally only mentioned if there are no FDA-approved drugs that impact that target. ** Numbers refer to clinicaltrials.gov identifier
(https://clinicaltrials.gov/ct2/show).
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3. Discussion
Our study demonstrates that the majority of hematologic tumors (~97%) had adequate tissue
for CGP interrogation. Further, of the 227 patients with adequate tissue, 75% harbored alterations
that could be prosecuted by a drug already in the clinical setting (Figure 1) (by an FDA-approved,
on-label drug (14%) or by an FDA-approved off-label drug (an additional 49% of patients) with the
rest targetable by experimental drugs in clinical trials). This finding is similar to observations in
solid tumors where up to 70% of patients have an alteration that was theoretically pharmacologically
tractable with an approved drug, and over 90% of patients have a potentially druggable alteration if
experimental drugs are included [39]. In contrast to solid tumors, however, with few exceptions, the
clinical utility of CGP for therapeutic decision-making for hematological malignancies has been limited
and genomic information has largely been confined to diagnosis, classification, and prognostication.
An example of such use is TP53 or ATM mutations in chronic lymphocytic leukemia (CLL), which
predict resistance to or short duration of response to chemotherapeutic agents [40]. Still, therapeutic
matching in AML is beginning to be reported, with notable examples being the FLT3 inhibitor
midostaurin and gilteritinib or the isocitrate dehydrogenase (IDH) inhibitors for patients with cognate
aberrations [9,27]. Overall, however, master precision medicine studies matching patients to diverse
cognate agents based on CGP are now being widely performed across solid tumors [2,3] but are in
nascent stages in the hematologic field.
Interestingly, as in solid tumors, there was great diversity in genomic portfolios in our patients [1].
Indeed, 148 distinct genes were altered in at least one patient and there were 546 unique genomic
alterations (Table 1). The vast majority of patients (95.5% of the 227 patients with adequate tissue) had
distinct genomic signatures. These findings suggest that customized combinations of drugs may be
needed for optimal matching.
The successful application of molecularly informed therapy has been demonstrated in
Waldenström’s macroglobulinemia (WM) lymphoplasmacytic lymphoma (LPL) where about 90%
of patients have a dominant mutation in MYD88L265P, an adapter protein used by toll-like receptors
that mediate signaling through Bruton tyrosine kinase (BTK) to promote proliferation and survival [41].
In a phase 2 trial, inhibition of BTK with ibrutinib achieved an overall response rate of 91% in previously
treated patients with WM [7]. Furthermore, as expected, the response rate to ibrutinib was significantly
higher in patients with MYD88 mutations vs. wild-type MYD88 genotype [7]. In our cohort, the MYD88
L265P mutation was found in one patient with WM as well as in four (of 18) patients with diffuse large
B-cell lymphoma (DLBCL), including one patient with a primary central nervous system lymphoma
(PCSNL). In the literature, MYD88 mutations have also been identified in marginal zone lymphoma
(MZL), CLL, DLBCL and PCNSL [42–45]. Preliminary data from a phase I trial of single-agent ibrutnib
in four patients with PCNSL demonstrated responses in two of the three patients evaluated [46].
Our data further confirms that mutations in MYD88 are readily identified by NGS. Trials in patients
with diverse malignancies and MYD88 mutations with BTK inhibitors may be warranted.
Activating mutations in BRAF were found in CLL (N = 3 of 39 patients; two with BRAF G469A
and one with BRAF V600E), multiple myeloma (N = 1 of 17; BRAF V600E), hairy cell leukemia (HCL)
(N = 1 of 1; BRAF V600E) and Erdheim Chester disease (ECD) (N = 1 of 1 patient; BRAF V600E).
These mutations are potentially targetable by the BRAF inhibitors vemurafenib and dabrafenib and
the MEK inhibitors trametinib and cobimetinib [4,17]. BRAF alterations have been identified as a
dominant driver mutation and as a biomarker for sensitivity to BRAF inhibition in HCL, ECD, and
myeloma [8,47–49]. BRAF alterations have been noted previously in 3% of patients with CLL [50].
In our studies, two CLL patients (5%) had mutations leading to alanine to glycine substitution
at position 469, which is an activating mutation in other tumors and confers sensitivity to BRAF
inhibition [51]. To our knowledge, this mutation has not been targeted in CLL previously. More
recently, Wander et al. also reported a t-AML patient with a BRAF V600E mutation, who was
refractory to several induction regimens, yet demonstrated a remarkable response to combined
targeted BRAF/MEK therapy (with dabrafenib and trametinib) as evidenced by restoration of normal
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hematopoiesis, clearance of peripheral blasts, and a significant reduction in marrow leukemic burden
with a concordant decrease in the BRAF V600E allelic burden [52]. Although transient, this patient’s
response serves as a proof of concept that targeting oncogenic driver mutations may have similar
efficacy in hematologic malignancies as in solid tumors supporting the emerging paradigm of designing
targeted therapies based on the presence of actionable lesions [53].
TMB has been shown to correlate to response with checkpoint inhibitors in solid tumors [54].
The vast majority of our 219 patients in whom TMB could be evaluated had a low TMB, but 12% (N = 26)
had an intermediate burden and 2% (N = 5 patients) had high TMB. Further, the mutational burden
was significantly higher in lymphoid versus myeloid malignancies (2.5 versus 0.9 mutations/MB,
respectively (p = 0.0012). This data is consistent with our previous analysis that showed that 32%
of patients with lymphoid malignancies had intermediate to high TMB [55]. Three of our patients
with higher TMB had mismatch repair gene alterations; in the solid tumor field, the PD-1 inhibitor
pembrolizumab has recently received approval for all patients with solid tumors and microsatellite
instability-high disease (which is due to mismatch repair alterations and is associated with a high TMB
and high response rate to anti-PD1 agents [56]. These results suggest that there may be a subset of
patients with hematologic malignancies who are amenable to response to checkpoint inhibitors as well.
Despite a wealth of clinical experience with molecularly matched therapies in solid tumor
oncology, some of these targetable alterations remain unexplored within the clinical realm of
hematology and present one of the major limitations of our study. This is partly due to the fact
that many of the theoretically applicable molecules are FDA-approved primarily in solid tumors [57].
Furthermore, there is still an incomplete consensus regarding what represents a targetable alteration,
and the necessary level of evidence needed to support the use of cognate agents in the clinic remains a
matter of debate. Thus, further studies assessing the role of therapy matched to genomic portfolios
across hematologic malignancies are certainly warranted.
4. Patients and Methods
4.1. Patients
We analyzed the genomic alterations by CGP and clinical characteristics of 235 patients with
diverse hematologic cancers seen at the UCSD Moores Cancer Center (La Jolla, CA, USA) from October
2012 through December 2016. This study was performed and consents obtained in accordance with the
guidelines of the UCSD Institutional Review Board (NCT02478931) (Center for Personalized Cancer
Therapy) (Center for Personalized Cancer Therapy).
4.2. Comprehensive Genomic Profiling (CGP)
We conducted CGP on tumor samples from lymph nodes, peripheral blood, bone marrow,
or tissue using FoundationOne Heme® (F1H; Foundation Medicine Inc., Cambridge, MA, USA),
a clinical grade, high-throughput, hybridization capture-based NGS assay for targeted sequencing of
all exons of 406 genes as well as RNA sequencing of 265 genes. F1H is a validated clinical laboratory
improvement amendments (CLIA)-approved, NY-state approved assay, and the methods used have
been previously reported in detail [58,59]. It is capable of simultaneously identifying all genomic
alterations, including insertions/deletions, base pair substitutions, copy number alterations (CNA),
and select gene rearrangements. Variants of unknown significance (VUSs) were not included in any of
our analyses except for tumor mutational burden (TMB) assessment.
4.3. Tumor Mutational Burden (TMB)
For TMB, the number of somatic mutations detected on NGS (interrogating 1.2 megabase (Mb)
of the genome) are quantified and that value extrapolated to the whole exome using a validated
algorithm [60,61]. Alterations likely or known to be bona fide oncogenic drivers and germline
polymorphisms are excluded. TMB was measured in mutations per MB. TMB levels were divided
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into three groups (per Foundation Medicine template): Low (1–5 mutations/MB), intermediate
(6–19 mutations/MB), and high (≥20 mutations/MB).
4.4. Definition of a Potentially Actionable Alteration
An alteration was designated as potentially actionable if there is ≥1 FDA-approved drug(s) or
experimental compounds in a clinical protocol that may impact the function of the protein product of
the alteration or its immediate downstream effectors, or that differentially distinguishes the protein in
cancerous versus normal cells. Small molecule inhibitors with 50% low inhibitory concentration for
the target and antibodies that recognize the protein were considered as impacting the target.
4.5. Data Analysis and Statistics
Pertinent data including patient demographics, tumor histology, and tissue source as well as
molecular testing results, number, and type of genomic alterations, were extracted from patients’
electronic medical records. Descriptive statistics (medians, means, ranges, and frequencies) were used.
5. Conclusions
In conclusion, we found that most patients with hematologic malignancies exhibit complex
molecular profiles that capture an array of oncogenic pathways across various histologies. The vast
majority of individuals have at least one or more genomic alterations that are potentially actionable
with existing drugs. A small subset of patients have intermediate/high tumor mutational burden,
a variable that has previously correlated with response to checkpoint inhibitor immunotherapy. These
observations present a window of opportunity for clinical trials to rationally test the application of
genomically targeted therapeutics or immunotherapy, particularly in relapsed/refractory patients who
have either exhausted or are unable to tolerate standard chemotherapy.
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